---
layout: post
title: What is RNAi therapy?
categories: Infographics
date:   2017-11-15
description: Targeting the Untargetable
image: assets/images/RNAi/Preview.png
permalink: /RNAi
---

#### RNA intereference or RNAi therapies have been imagined decades ago. However they will only arrive on the market in 2018. Why are RNAi therapies exciting and why the wait was so long?

Gene expression can be modulated at different level : at the DNA level in the nucleus and also at the mRNA level in the cytoplasm. RNAi allow cells to modulate their gene expression after the RNA has been synthetised and before it is translated completly into a protein. 


![My helpful RNAi infographic](assets/images/RNAi/171113_RNAi.png)

### References

##### Science Articles
1. [Bobbin M and Rossi J. (2016). RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? _Annu. Rev. Pharmacol. Toxicol._](https://www.ncbi.nlm.nih.gov/pubmed/?term=26738473){:target="_blank"}
2. [Chakraborty C. _et al._ (2017). Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. _Molecular Therapy: Nucleic Acids_](https://www.ncbi.nlm.nih.gov/pubmed/?term=28918016){:target="_blank"}
3. [Dowdy S. (2017). Overcoming cellular barriers for RNA therapeutics. _Nature Biotechnology_](https://www.ncbi.nlm.nih.gov/pubmed/?term=28244992){:target="_blank"}
4. [Lam J. _et al._ (2015). siRNA Versus miRNA as Therapeutics for Gene Silencing. _Molecular Therapyâ€”Nucleic Acids Vol_](https://www.ncbi.nlm.nih.gov/pubmed/?term=26372022) {:target="_blank"}

##### Web
1. [Labiotech.eu, "RNA as a Therapy: Reviewing the Future Generation of Therapeutics"](https://labiotech.eu/rna-review-rnai-mrna/){:target="_blank"}
2. [Labiotech.eu, "Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?"](https://labiotech.eu/ultimate-review-how-could-mrna-overtake-all-other-biologicals-in-medicine/)
3. [Alynam - "Our pipeline"](http://www.alnylam.com/alnylam-rnai-pipeline/){:target="_blank"}

##### Clinical trial listed
* Cancer
  - miRNA mimic: MRX-34 (Mirna) - [Phase I (alted) - NCT01829971](https://clinicaltrials.gov/ct2/show/NCT01829971)
  - siRNA: siG12D LODER (Silenseed) - [Phase I/II completed - NCT01188785](https://clinicaltrials.gov/ct2/show/NCT01188785){:target="_blank"}
* Ophtalmologic:
  - miRNA: preclinical
  - siRNA: Bevasiranib (OPKO) - [Phase III abandoned - NCT00499590](https://clinicaltrials.gov/ct2/show/NCT00499590){:target="_blank"}
* Genetic:
  - miRNA: miRNA inhib: RG-012 (Regulus/Sanofi) - [Phase II - NCT02855268](https://clinicaltrials.gov/ct2/show/NCT02855268){:target="_blank"}
  - siRNA: Partisan (Alnylam) - [Phase III NCT01960348](https://clinicaltrials.gov/ct2/show/NCT01960348){:target="_blank"} & [NCT02510261](https://clinicaltrials.gov/ct2/show/NCT02510261){:target="_blank"}
* Infection: 
  - miRNA inhib: miravirsen (Santaris) - [Phase IIa - NCT01872936](https://clinicaltrials.gov/ct2/show/NCT01872936){:target="_blank"}
  - siRNA: ALN-RSV01 (Alnylam) - [Phase IIb completed - NCT01065935](https://clinicaltrials.gov/ct2/show/NCT01065935){:target="_blank"}
* Metab-cardio: 
  - miRNA inhib: RG-125 (Regulus/Sanofi) - [Phase I/IIa - NCT02826525](https://clinicaltrials.gov/ct2/show/NCT02826525){:target="_blank"}
  - siRNA: fitusiran (Alnylam/Sanofi) -  [Phase III - NCT02035605](https://clinicaltrials.gov/ct2/show/NCT02035605){:target="_blank"}
* Others:
  - miRNA mimics: MRG-201 (miRagen) - [Phase I NCT02603224](https://clinicaltrials.gov/ct2/show/NCT02603224){:target="_blank"}
  - siRNA: RX1-109 (RXi Pharma) - [Phase II - NCT02246465](https://clinicaltrials.gov/ct2/show/NCT02246465){:target="_blank"}